Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.

You may also be interested in...



Fosrenol Approved In Higher Dose Formulation

FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28

Fosrenol Approved In Higher Dose Formulation

FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28

Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care

Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel